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nucleosides and nucleotides are reviewed in which the author played a signiﬁcant part, especially
in the initial stages of their development. Highlighted are the amino acyl esters of acyclovir,
particularly valacyclovir (VACV), brivudin (BVDU) and the valine ester of Cf1743 (FV-100), the
20,30-dideoxynucleosides (nucleoside reverse transcriptase inhibitors, NRTIs), the acyclic nucleoside
phosphonates (S)-HPMPA, (S)-HPMPC (cidofovir) and alkoxyalkyl esters thereof (HDP-, ODE-
CDV), adefovir and adefovir dipivoxil, tenofovir and tenofovir disoproxil fumarate (TDF),
combinations containing TDF and emtricitabine, i.e., Truvadas, Atriplas, Compleras/Evipleras
and the Quad pill, and the phosphonoamidate derivatives GS-7340, GS-9131, GS-9191 and
GS-9219.
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Figure 1 Prodrugs of acyclovir, ganciclovir and penciclovir.
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The era of antiviral drug therapy started with idoxuridine
(IDU) and triﬂuridine (TFT). IDU was ﬁrst synthesized as a
potential anticancer drug by Prusoff in 19591; it was ﬁrst
shown in 1961 to possess activity against herpes simplex virus
(HSV) and vaccinia virus by Herrmann2, before it was
launched in the clinic, for the topical treatment of herpetic
keratitis by Kaufman3. Two years later, Kaufman and
heidelbrger4 also unleashed triﬂuridine (TFT) for the topical
treatment of herpetic keratitis. As of today, IDU and TFT are
still used in the topical treatment of herpetic eye infections.
Still in the 1960s, arabinosyladenine (ara-A), originally
synthesized as a potential anticancer agent by Lee et al.5 was
ﬁrst shown by Privat de Garilhe and de Rudder6 to be active
against HSV and vaccinia virus before it was further described
as an antiviral agent by Schabel7, before it became the ﬁrst
antiviral drug to be used systemically, i.e., by Whitley et al.8 in
1976, in the therapy of varicella-zoster virus (VZV) infections.
Ara-A is no longer used in the clinic, essentially for a number
of reasons: it has low aqueous solubility, is rapidly deaminated
to the inactive arabinosylhypoxanthine (ara-Hx), but primar-
ily, because it was superseded from the 1980s by acyclovir.
Meanwhile, in the early 1970s ribavirin (virazole) had been
described by Sidwell et al.9 as a broad-spectrum antiviral
agent. For circa 30 years, ribavirin was looking for a disease
against which it could be useful, until it found its niche,
together with pegylated interferon, in the treatment of chronic
hepatitis C virus (HCV) infections. The combination of
pegylated interferon-a with ribavirin has since the last 10
years been the standard of care (SOC) for the treatment of
HCV infections, but is likely to be, ﬁrst complemented and
then replaced by direct-acting antiviral agents (DAAs).
Of crucial importance in the treatment of herpesvirus (i.e.,
HSV and VZV) infections was the discovery of acyclovir, the
ﬁrst truly speciﬁc antiviral agent, by Elion et al.10 and
Schaeffer et al11. Now, 35 years after it was originally
described, acyclovir can still be considered as the ‘‘gold
standard’’ for the treatment of HSV and VZV infections12.
How the antiviral research ﬁeld, that started with the
nucleoside analogs IDU, TFT, ara-A, ribavirin and acyclovir,
further evolved (and thrived) will be the subject of the present
review. This review will focus speciﬁcally on nucleoside
analogs such as amino acyl acyclovir esters, bromovinyldeox-
yuridine and 20,30-dideoxynucleoside analogs, and nucleotide
analogs (i.e., acyclic nucleoside phosphonates (ANPs)).
Twenty-ﬁve years ago, the era of the ANPs started with the
birth of (S)-HPMPA. It has now grown to a large family of
marketed drugs, including cidofovir, adefovir and tenofovir,
and various prodrugs and drug combinations derived thereof.2. Antiviral agents
2.1. Valacyclovir (VACV)
Acyclovir suffers from some drawbacks in that it is relatively
insoluble in aqueous medium and poorly absorbed after oral
administration. To circumvent the ﬁrst problem, amino acid
(i.e., glycine, alanine) esters of acyclovir (Fig. 1) were synthe-
sized13. An advantage of such amino acyl esters is that for
topical use, i.e., for the treatment of herpetic keratitis, they canbe administered as eye drops14, whereas acyclovir has to be
applied as an eye ointment. A second advantage of such amino
acyl esters is that for systemic use they could be injected
intramuscularly or subcutaneously, in small volumes, whereas
the parent compound, acyclovir, has to be administered
intravenously in large volumes. However, from a practical
viewpoint, parenteral injection of the amino acid esters of
acyclovir has never been pursued.
Of the various amino acid esters of acyclovir that were
subsequently studied, the valine ester, valacyclovir (Zelitrexs,
Valtrexs) (Fig. 1) appeared to be the most suitable for
increasing the oral bioavailability of acyclovir15, and valacyclo-
vir has now replaced acyclovir in the oral treatment of HSV and
VZV infections. Likewise, to increase the oral bioavailability,
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famciclovir, the prodrug of penciclovir (Fig. 1), were introduced
for the oral treatment of, respectively, cytomegalovirus (CMV)
infections and HSV and VZV infections15.
VACV is the only antiviral drug approved for once-daily
suppressive therapy for genital herpes16. VACV has been FDA-
approved for the treatment of HSV and VZV infections in
immunocompromised patients. It is more effective than acyclovir
in the treatment of herpes zoster, particularly with regard to the
duration of post-herpetic neuralgia (mean duration of pain: 40
days as compared to 60 days)17. VACV at a dose of 1 g twice
daily from month 4 to 24 after hematopoietic stem cell
transplantation was found effective in suppressing herpes zos-
ter18. Oral VACV could also be recommended for early treat-
ment of HSV encephalitis in resource-limited settings19.
Single-day famciclovir (1000 mg administered twice daily)
proved as effective as a 3-day VACV regimen (500 mg adminis-
tered twice daily) for recurrent genital herpes20. One-year
suppressive therapy with oral VACV (500 mg daily) was shown
to be as effective and as well tolerated as acyclovir (400 mg twice
daily) in reducing the rate of recurrent ocular HSV disease21.
Administration of VACV (500 mg twice daily) beginning at
36 weeks’ gestation until delivery to women with a history of
recurrent genital HSV reduced the number of subsequent
clinical HSV recurrences22. Exposure to acyclovir or VACV
in the ﬁrst trimester of pregnancy was not associated with an
increased risk of major birth defects23.
Preemptive valganciclovir and VACV prophylaxis would
be equally effective in the prevention of CMV disease
after renal transplantation24. Valganciclovir and VACV wereFigure 2 Synthetic scheme of FV-100.similarly protective against CMV disease25. VACV reduced
the frequency of Epstein-Barr virus (EBV)-infected B cells
when administered for a long period (one year) and might
allow eradication of EBV from the body if reinfection does not
occur26. Whether VACV may be of clinical beneﬁt in the
treatment of acute infectious mononucleosis remains subject
of large, placebo-controlled clinical trials27.
The conversion of VACV to acyclovir, and of valganciclovir
to ganciclovir, is catalyzed by valacyclovirase, an a-amino acid
ester hydrolase28. Curiously, VACV has been shown to inhibit
erythrocyte sickling in vitro29,30. Acyclovir is known to be
transported into human erythrocytes31, but what further
happens with acyclovir in the red blood cells is not known.
Ender et al.30 now suggest that VACV may be of potential
utility as an anti-sickling agent in sickle-cell anemia.2.2. BVDU and FV-100
IDU (idoxuridine) and TFT (triﬂuridine), the ﬁrst 5-
substituted 20-deoxyuridines (dUrds) to be recognized as
antiviral drugs (Fig. 2), have only proved useful for topical
administration, for the treatment of herpetic keratitis, as they
are too toxic for systemic administration32. The ﬁrst (and so
far only) 5-substituted dUrd used in many countries (except
for the US and UK) for the treatment of herpes zoster, is
BVDU [(E)-5-(2-bromovinyl)-20-deoxyuridine, brivudin]. It
was ﬁrst identiﬁed as a highly speciﬁc inhibitor of HSV type
133 and VZV. In fact, the efﬁcacy of BVDU against herpes
zoster was ﬁrst reported in patients34, before its potency and
Erik de Clercq538selectivity as an anti-VZV agent in cell culture was demon-
strated by Shigeta et al35.
BVDU (Fig. 2) was ﬁrst approved for clinical use (as
Helpins) in the former DDR (East Germany) in immunosup-
pressed patients, before it was licensed for clinical use in
immunocompetent persons for the treatment of herpes zoster.
It is now available in several countries, under differentFigure 3 Structures of ddN analogues.trade names (Zostexs (Germany); Briviracs (Italy); Zerpexs
(Belgium)). While even more active than acyclovir against
both HSV-1 and VZV, BVDU is speciﬁcally used for the
treatment of VZV infections (herpes zoster)36. It owes its
selective anti-VZV activity to a speciﬁc phosphorylation by the
VZV-encoded thymidine kinase to the mono- and dipho-
sphate, which upon further phosphorylation by the (cellular)
Discovery of antiviral agents 539nucleoside diphosphate (NDP) kinase to the triphosphate,
interferes with the viral DNA synthesis.
Recent review articles have pointed to FV-100 as an
emerging new candidate drug for the treatment of VZV
infections37–39. Migliore39 qualiﬁed FV-100 as the most potent
and selective anti-VZV agent reported to date.
Where did FV-100 originate from? The parent compound of
FV-100 (FV standing for ‘‘Fermavir’’) is Cf1743 (Cf standing for
‘‘Cardiff’’) (Fig. 2). Cf1743 belongs to the so-called BCNAs
(bicyclic furopyrimidine nucleoside analogs) originally described
by McGuigan et al40,41. Cf1743 is the most potent of a class of
compounds that are speciﬁcally active against VZV. The mechan-
ism of action of Cf1743 still needs to be elucidated but clearly
depends on a speciﬁc phosphorylation by the VZV-encoded
thymidine kinase42. Its potency against VZV exceeds that of all
other antiviral agents including BVDU43.
FV-100 is the 50-valine ester of Cf174344 (Fig. 2) and in this
sense related to the valine esters of acyclovir and ganciclovir
(Fig. 1). FV-100 has recently been the subject of 3 randomized,
double-blind, placebo-controlled clinical trials45. These studies
support further investigations with FV-100 (at a daily dosage
of 100 mg, 200 mg, 400 mg or 800 mg, for 7 days) for the
treatment of herpes zoster45. Herpes zoster patients can now
be monitored for VZV DNA in the saliva46. Such non-invasive
analysis would allow to follow the response of VZV infection
to anti-VZV agents such as VACV, BVDU and FV-100.Figure 4 Structures of (S)-HPMPC and (S)-HPMPA.2.3. 20,30-Dideoxynucleoside (ddN) analogs
The ﬁrst 20,30-dideoxynucleoside (ddN) described, in 1985, for
its inhibitory effect on the infectivity and cytopathicity of HIV
(then called HTLV-III for human T-cell lymphotropic virus
type 3) was azidothymidine (AZT, retrovirs) (Fig. 3)47.
This compound was discovered serendipitously as an anti-
HIV agent, as it had been originally synthesized as a potential
anticancer agent by Horwitz et al48. In fact, in 1980 we had
described the anti-HSV activity of several ddN analogs,
including azidothymidine49. The mechanism of anti-HIV
action of azidothymidine was described by Furman et al50.
It resided in the inhibitory effect of its 50-triphosphate as an
HIV alternate substrate/competitive inhibitor on the reverse
transcriptase (RT).
Following azidothymidine, several other 20,30-dideoxynu-
cleoside analogs, including dideoxyinosine (ddI, didanosine,
Videxs, Videx ECs) and dideoxycytidine (ddC, zalcitabine,
Hivids) (Fig. 3) were found inhibitory to the infectivity and
cytopathicity of HIVal 51. Like AZT, ddI and ddC were found
to inhibit the HIV RT as chain terminators, ddI, following its
conversion to ddATP in competition with dATP, and ddC,
following its conversion to ddCTP in competition with dCTP,
both dATP and dCTP being regular substrates for the RT
reaction.
Following AZT, ddI and ddC, the fourth ddN analog to be
discovered was d4T (stavudine, Zerits), which was announced
successively by Baba et al52. Lin et al.53 and Hamamoto
et al54. The mode of action of d4T was resolved by Balzarini
et al55. It would become one of the most popular, world-wide
used anti-HIV drugs, later to be superseded only by tenofovir
(see infra).
Following stavudine (d4T), three more ddN analogs, lamivu-
dine (3TC), abacavir (ABC) and emtricitabine [(–)FTC] wouldsubsequently be licensed as anti-HIV drugs56,57. Lamivudine was
originally discovered by the late Belleau58 as a racemic mixture of
which the (–)enantiomer (3TC) was proven to be most active.
The anti-HIV activity of abacavir was originally described
by Daluge59, whereas the discovery of (–)FTC was credited to
Schinazi60. 3TC, ABC, and (–)FTC would later be commercia-
lized under the trade names of Epivirs, Ziagens and Emtrivas,
respectively.
Although many more ddNs than those reported above,
have been reported in the meantime, the number of approved
ddN analogs (now also referred to as nucleoside reverse
transcriptase inhibitors (NRTIs)) have been limited to the
seven ddN analogs shown in Fig. 3. In the past few years, no
more ddN analogs or NRTIs have been added to the current
anti-HIV drug armamentarium. Instead, further progress in
the ﬁeld of anti-HIV therapy has been focused on the judicious
choice of combination of the appropriate NRTIs (such as
Emtrivas) with the appropriate NtRTIs (such as tenofovir
disoproxil fumarate) and NNRTIs (such as efavirenz and
rilpivirine) (see infra: Atriplas and Compleras/Evipleras).2.4. (S)-HPMPA and (S)-HPMPC (Cidofovir)
The era of the acyclic nucleoside phosphonates (ANPs)61 started
in 1986 with the description of (S)-HPMPA [(S)-9-(3-hydroxy-2-
phosphonylmethoxypropyl)adenine] as a novel selective broad-
spectrum anti-DNA virus agent62. One year later followed the
description of (S)-HPMPC [(S)-1-(3-hydroxy-2-phosphonyl-
methoxypropyl)cytosine], the cytosine counterpart (cidofovir) of
(S)-HPMPA (Fig. 4)63. (S)-HPMPC showed an activity spectrum
similar to that of (S)-HPMPA; nine years later, in 1996, it would
be formally approved as Vistides for the treatment, by intrave-
nous injection, of CMV retinitis in AIDS patients. This indication
has virtually disappeared with the efﬁcient treatment of AIDS.
Yet, cidofovir is still used off label in the treatment of poxvirus
infections (i.e., molluscum contagiosum) and human papilloma-
virus (HPV) infections. It has proven more efﬁcacious than
smallpox vaccination upon lethal monkeypox virus infection64.
Cidofovir bears an hydroxyl group that is equivalent to the
30-hydroxyl group of dCMP and permits its incorporation into
DNA, creating a signiﬁcant impediment to trans-lesion DNA
synthesis in a manner resembling DNA damage65. This leads
for vaccinia virus to an inhibition of genome encapsidation
and virus assembly66.
Cidofovir has proven highly effective in different models of
poxvirus infection, whether the compound was administered
either intraperitoneally, intranasally or topically67, including
Erik de Clercq540camelpox in athymic nude mice68 as well as an aerosol
rabbitpox model69. Also, the sea lion parapoxvirus has proven
susceptible to cidofovir70. When co-administered with the
smallpox vaccine, cidofovir effectively reduced vaccination
side effects71.
In earlier reports, both topical and systemic cidofovir were
shown to resolve recalcitrant molluscum contagiosum virus
lesions72–75. The efﬁcacy of intravenous cidofovir in the
treatment of giant molluscum contagiosum was most drama-
tically shown recently in a patient with HIV infection76.
Intralesional cidofovir has proven successful in the treat-
ment of acyclovir-resistant HSV infection77, whereas intrave-
nous cidofovir was used successfully in the treatment of dual
infection with polyomavirus BK and acyclovir-resistant HSV
in a bone marrow transplant recipient78. Cidofovir may be a
potentially effective therapy for the treatment of BK virus-
associated hemorrhagic cystitis, a severe complication after
allogeneic hematopoietic stem cell transplantation (HSCT)79.
BK virus-associated nephopathy in a kidney transplant reci-
pient was successfully treated with cidofovir, the ﬁrst case in
Japan80.
Cidofovir markedly reduced the growth of HPV-positive
cervical cancer cell xenografts in nude mice81. This result was
conﬁrmed in a clinical setting where cidofovir proved effective
in the topical treatment of cervical intraepithelial neoplasia
(CIN) stage 282.
The principal off-label use of cidofovir, however, is cur-
rently for intralesional injection for recurrent respiratory
papillomatosis in both children83 and adults84, and, even more
so, the local administration of cidofovir for HPV-associated
skin lesions in transplant recipients85. Successful treatment of
cutaneous warts has been reported with intravenous cidofovir
in an 11-year old girl86, and several case reports have pointed
to the successful use of topical cidofovir at 1% in the
treatment of HPV warts in children87–89.2.5. CMX001 (HDP-CDV)
CMX001 (HDP-CDV) (Fig. 5) corresponds to hexadecylox-
ypropyl cidofovir, an ether lipid conjugate of cidofovir, which,
in principle, should be active against the same DNA viruses
against which cidofovir itself is active, but, in comparison with
CDV, CMX001, should have increased oral bioavailability
and increased cellular uptake, facilitated by the lipid moiety of
the molecule90. The increased cellular uptake accounts for the
increased antiviral activity of HDP-CDV91. Its oral activityFigure 5 Structures of HDP-CDV and ODE-CDV.has been demonstrated particularly for the treatment of
smallpox92 and in a lethal mousepox model93.
Preclinical studies have demonstrated the efﬁcacy of
CMX001 in the treatment of vaccinia and cowpox virus
infections in mice, which suggested that the compound could
be used in the event of a bioterror attack by poxviruses94. The
advantage of CMX001 over its parent compound, cidofovir, is
that it could be administered orally (as a tablet or liquid)
(presumably) without nephrotoxicity, which limits the dosing
of the parent compound95. It has proven efﬁcacious as a post
exposure antiviral in rabbits infected with rabbitpox virus, a
model for orthopoxvirus infection of humans96.
In pregnant guinea pigs, CMX001 improved he outcome
of congenital CMV infection97, suggesting the potential of
CMX001 for the treatment of congenital CMV infection in
humans. CMX001 may also be effective in the treatment of
acyclovir-resistant HSV infection, and combination of
CMX001 with acyclovir led to a synergistic inhibition of
HSV infections98.
CMX001 has been shown to prevent adenovirus-induced
mortality in a permissive immunosuppressed animal model
(cyclophosphamide-treated hamsters)99, and in a pediatric
hematopoietic stem cell transplantation recipient CMX001
led to the eradication of disseminated adenovirus infection100.
CMX001 also seems effective in the treatment of human
polyomavirus replication in primary human renal tubular
epithelial cells101, polyoma JC virus replication in human fetal
brain SVG cell cultures102 and polyomavirus JC replication in
human brain progenitor-derived astrocytes103.
In addition to CMX001, various other prodrugs of cidofo-
vir have been reported, i.e., Ala–Ser and Val–Ser prodrugs104.
Similarly, tyrosine-based prodrugs of cidofovir have been
synthesized which may be of potential use in the treatment
of the same DNA virus infections that are susceptible to
cidofovir105. The advantage of these prodrugs, if any, over
that of the parent compound, cidofovir, remains to be
demonstrated.2.6. HDP-(S)-HPMPA
Alkoxypropyl, i.e., hexadecyloxypropyl (HDP) and octadecy-
loxyethyl (ODE) esters have been prepared from both
(S)-HPMPC and (S)-HPMPA. (S)-HPMPA was the prototype
of the acyclic nucleoside phosphonates62, which was never
commercialized for clinical use. The reason why (S)-HPMPC
(cidofovir), PMEA (adefovir), and (R)-PMPA (tenofovir) were
successfully introduced in clinical medicine, whereas the
Discovery of antiviral agents 541prototype compound (S)-HPMPA was not, even not for any
of the DNA virus infections for which it was more effective
than (S)-HPMPC, has remained an enigma.
HDP-(S)-HPMPA and ODE-(S)-HPMPA (Fig. 6) were
recently reported to be active against HIV replication106.
This was not surprising given the broad-spectrum anti-
DNA virus activity of the parent compound, (S)-HPMPA62.
More surprising was the activity reported for ODE- and
HDP-(S)-HPMPA against hepatitis C virus (HCV), which,
being an RNA virus, was certainly not expected to be
sensitive to the inhibitory action of acyclic nucleoside
phosphonates107.
Of the alkoxyalkyl esters, the most active anti-HCV agent was
ODE-(S)-3-methoxy-2-(phosphonylmethoxy)propyl-guanine with
an EC50o0.01 nM and a selectivity index of 44.4 million106.
(S)-HPMPA has been found active against parasites, i.e., the
growth of Plasmodium falciparum and P.berghei108,109. The HDP-
cyclic(S)-HPMPA was found to have antischistosomal activity110,
and this has given a new impetus to a long forgotten therapeutic
potential of (S)-HPMPA and acyclic nucleoside phosphonates,Figure 7 Structures of adefovir, adefovir dipivoxil, tenofovir and TD
Figure 6 Structures of HDP-(S)-HPMPA and ODE-(S)-HPMPA.their unexplored therapeutical potential in the treatment of
malaria and other parasitic infections.
ODE and HDP esters of HPMPA are potent inhibitors of
HIV111, while its parent compound has not been recognized as an
anti-HIV agent. Alkoxyalkyl esters of (S)-HPMPAmay, like those
of cidofovir, exhibit wide spectrum antiviral activity against pox-,
adeno-, herpes-, cytomegalovirus infections, with HDP-(S)-
HPMPA being at least as promising as HDP-(S)-HPMPC as
orally active against various DNA virus infections112.2.7. Adefovir and tenofovir
The oral bioavailability of cidofovir (CDV) is increased by linking
CDV to an alkoxyalkyl ester, as in hexadecyloxypropyl (HDP)-
CDV (see supra, section 2.5). The oral prodrugs designed for
adefovir (ﬁrst described by de Clercq et al.62) and tenofovir (ﬁrst
described by Balzarini et al.113) have been adefovir dipivoxil (AD,
Hepseras) and tenofovir disoproxil fumarate (TDF, Vireads)
(Fig. 7). The design of AD and TDF has made the parentF.
Erik de Clercq542compounds adefovir and tenofovir rapidly available, through
cleavage of the ester bonds, after oral administration.
Adefovir dipivoxil [bis(pivaloyloxymethyl)-9-(2-phosphonyl-
methoxyethyl)adenine] has been described by Starrett et al.114,
Cundy et al.115,116 and Shaw et al117.
The pioneering clinical studies of Hadziyannis et al.118 and
Marcellin et al.119 helped the approval of Hepseras, in 2002,
for the treatment of chronic hepatitis B. These results were
nicely conﬁrmed by a cross-over study upon long-term




described by Robbins et al.121 and Naesens et al.122 Teno-
fovir disoproxil fumarate (TDF) was approved for clinical
use for the treatment of HIV infection (AIDS) in 2001, and
for the treatment of chronic HBV infection in 2008. As to
the latter, the key observation was that TDF at a daily dose
of 300 mg had superior antiviral activity with a similar
safety proﬁle as compared to adefovir dipivoxil at a daily
dose of 10 mg123.
Twenty years after its original discovery, tenofovir has acquired
a crucial position in the ﬁght against HIV: it is not only efﬁcacious
against AIDS but also hepatitis B; it can be used in combination
with emtricitabine, efavirenz, rilpivirine, elvitegravir, atazanavir, or
darunavir, as a single once-daily oral pill; and it can be used
in combination with emtricitabine as a once-daily oral pill,
Truvadas, in the prophylaxis of sexual HIV transmission124.
The increased oral bioavailability and increased cellular
uptake noted for the hexadecyloxypropyl derivative of cido-
fovir (see supra, section 2.5) also holds for tenofovir. Hex-
adecyloxypropyl tenofovir (CMX157) shows markedly
increased oral bioavailability and cellular uptake as compared
with the parent compound125,126.Figure 8 Drug combination of Quad.For the treatment of HBV infections, there are ofﬁcially six
compounds available: interferon-a, lamivudine (3TC), adefo-
vir dipivoxil, entecavir, telbivudine and TDF. For HIV
infections, however, 25 years after the discovery of HIV, there
are now more than 25 compounds approved as anti-HIV
drugs56,57. Tenofovir, in its oral prodrug form, TDF, is the
cornerstone for the treatment of HIV infections127,128, appar-
ently due to the magic of the phosphonate bond129.2.8. Truvada, Atripla, Complera, Quad (Stribild TM)
When ﬁrst approved in 2001, Vireads could hardly be
anticipated to grow to a double-drug combination (Truvadas)
in 2004, a triple-drug combination (Atriplas) in 2006, another
triple-drug combination (Compleras in the US, Evipleras in
the EU) in 2011, and even a quadruple-drug combination
Quad (Stribild TM) in 2012 (Fig. 8). The single once-daily oral
pill containing three active ingredients (Truvadas and efavir-
enz) was Atriplas130. Then followed Compleras/Evipleras,
like Atripla, containing three active ingredients: Truvadas
and rilpivirine (Edurants) (Fig. 8)131.
Scheduled for 2012 is the ﬁrst Quad pill, containing in
addition to Truvadas, the integrase inhibitor (INI) elvitegra-
vir and the pharmacoenhancer cobicistat (Fig. 8). Also
expected to be approved in 2012 is Truvadas for prophylactic
use to prevent sexual transmission of HIV infection.
In addition to the ‘‘real’’ Quad (Quad no. 1 Stribild TM)
containing elvitegravir, cobicistat, emtricitabine and TDF, several
other Quads are forthcoming131: Quad no. 2, consisting of
Truvadas, cobicistat and atazanavir; Quad no. 3, consisting of
GS-7340, emtricitabine ((–)FTC), cobicistat and darunavir; and
Quad no. 4, consisting of GS-7340, emtricitabine ((–)FTC),
cobicistat and elvitegravir131.
Figure 9 Structures of GS-7340, (R)-PMPA, GS-9131 and GS-9148.
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GS-7340 (Fig. 9) (see supra, section 2.8) is an isopropylalaninyl
monoamidate phenyl monoester prodrug of tenofovir; it was ﬁrst
described by Lee et al132. Phosphonoamidate prodrugs of
adefovir and tenofovir had originally been described by Ballatore
et al133. A novel one-pot synthesis of bis-amidate prodrugs of
acyclic nucleoside phosphonates was reported by Jansa et al134.
GS-9131 (Fig. 9) is the orally bioavailable phosphonoami-
date prodrug of GS-9148, a cyclic nucleoside phosphonate
analogue135 with a low nephrotoxic potential136. The 20-ﬂuoro
group fulﬁlls a speciﬁc role in this compound, as it may cause
steric hindrance to the side chain of the Q151L mutation137.
Cathepsin A is the major hydrolase catalyzing the intracellular
hydrolysis of GS-7340 to tenofovir and of GS-9131 to GS-
9148138. Cathepsin is also held responsible for the intracellular
hydrolysis of GS-9191 to cPrPMEDAP139. GS-9191 can be
considered as a ‘‘double’’ prodrug, being converted to PMEG
via cPrPMEDAP as intermediate, thus requiring hydrolysis
followed by deamination to yield PMEG, which is then
converted to PMEG diphosphate as the ﬁnal active metabolite.
GS-9191 has been pursued for the topical treatment of
human papilloma virus (HPV) infections140. cPrPMEDAP
could also be directly applied topically or transdermally141.
Like GS-9191, GS-9219 (Fig. 10) is a double prodrug of
PMEG via cPrPMEDAP: it has potent antineoplastic activity
in dogs with spontaneous non-Hodgkin’s lymphoma142,143.
As for GS-9191, the ﬁnal active metabolite of GS-9219 is
assumed to be PMEG diphosphate142.
3. Conclusions
The principal conclusions reached from this overview are as
follows:3.1. Valacyclovir (VACV) has succeeded acyclovir as the
gold standard for the oral treatment of both herpessimplex virus (HSV) and varicella-zoster virus (VZV)
infections;3.2. BVDU (brivudin) and FV-100 (the valine ester of Cf1743)
have remained the most potent inhibitors of VZV
infections; Cf1743 does not suffer from the liability of
potentiating the toxicity of 5-ﬂuorouracil, as noted for
bromovinyluracil, the degradation product of BVDU;3.3. Most of the 20,30-dideoxynucleoside (ddN) analogs that
have been licensed for clinical use, are still used for the
treatment of human immunodeﬁciency virus (HIV)
infections, i.e. (–)FTC (emtricitabine) in combination
with tenofovir disoproxil fumarate (TDF);3.4. The acyclic nucleoside phosphonates (S)-HPMPA and
(S)-HPMPC (cidofovir) possess broad-spectrum anti-
viral activity against DNA (pox, herpes, adeno, papil-
loma, polyoma) viruses;3.5. The alkoxyalkyl (HDP: hexadecyloxypropyl, ODE: octa-
decyloxyethyl) esters of (S)-HPMPA and (S)-HPMPC
show increased oral bioavailability and increased cellular
uptake as compared to the parent compounds;3.6. Adefovir dipivoxil, the prodrug of PMEA, is widely
accepted for the treatment of hepatitis B virus (HBV)
infections, whereas tenofovir disoproxil fumarate, the
prodrug of (R)-PMPA, is widely used for the treatment
of both HIV and HBV infections;3.7. Combinations containing TDF and (–)FTC (Truvadas),
if extended with efavirenz to Atriplas, or with rilpivirine
to Compleras (or Evipleras) are available as single pills
for once-daily use in the treatment of HIV infections.
was recently appeared is the Quad pill containing TDF,
(–)FTC, elvitegravir and cobicistat Quad (Stribild TM).3.8. In development are phosphonoamidate prodrugs,
i.e., GS-7340 and GS-9131, for the oral treatment of
HIV infections, GS-9191 for topical treatment of human
papilloma virus (HPV) infections, and GS-9219 for the
treatment of non-Hodgkin’s lymphoma (NHL) in dogs.
Figure. 10 Structures of prodrugs of PMEG.
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